Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Review Memorandum - June 22, 2009 - Hiberix

Food and Drug Administration
Center for Biologics Evaluation and Research
Office of Compliance and Biologics Quality
Division of Case Management
Advertising and Promotional Labeling Branch

 

REVIEW MEMORANDUM

Date:  June 22, 2009

To:   Elisa Harkins
        Associate Director, North American Regulatory Affairs
        GlaxoSmithKline

Through:  Ele Ibarra-Pratt, RN, MPH, Branch Chief
                Advertising and Promotional Labeling Branch (APLB)

From:  Maryann Gallagher, Consumer Safety Officer
         APL

Product:  Hiberix [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)]
              STN# 125347
               Sponsor: GSK


The Advertising and Promotional Labeling Branch (APLB) reviewed the revised proposed product logo that you submitted for advisory comment on June 11, 2009 to the BLA for Hiberix [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)].  We have reviewed the proposed logo and we have no concerns at this time. 

If you have any questions, please contact Maryann Gallagher, Consumer Safety Officer at 301-827-3028.

Page Last Updated: 09/24/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.